P683: TRIALS IN PROGRESS: FIRST-IN-HUMAN STUDY OF ELVN-001, A SELECTIVE BCR::ABL1 TYROSINE KINASE INHIBITOR, IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WHO FAILED PREVIOUS TYROSINE KINASE INHIBITOR THERAPIES

P683: TRIALS IN PROGRESS: FIRST-IN-HUMAN STUDY OF ELVN-001, A SELECTIVE BCR::ABL1 TYROSINE KINASE INHIBITOR, IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WHO FAILED PREVIOUS TYROSINE KINASE INHIBITOR THERAPIES

Bibliographic Details
Main Authors:	Fabian Lang, Susan Branford, Joseph P. Lyssikatos, Helen Collins, Andreas Hochhaus
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000969636.32603.d4

Similar Items

Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
by: Francesca Carofiglio, et al.
Published: (2020-06-01)

The Effect of BCR-ABL Specific Tyrosine Kinase Inhibitors on the Thioredoxin System in Chronic Myeloid Leukemia
by: Erin Clapper, et al.
Published: (2021-05-01)

Simvastatin enhances the efficacy of Bcr-Abl tyrosine kinase inhibitor nilotinib in chronic myeloid leukemia.
by: Koh, Yanqing.
Published: (2011)

Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance
by: Aghel N, et al.
Published: (2017-08-01)

Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors.
by: Yihua Wang, et al.
Published: (2023-01-01)

Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study
by: Zahidah Abu Seman, et al.
Published: (2024-04-01)

Adverse Reaction Profiles Related to Gastrointestinal Bleeding Events Associated with BCR-ABL Tyrosine Kinase Inhibitors
by: Kei Kawada, et al.
Published: (2022-10-01)

The Role of Mitochondrial DNA Damage and Repair in the Resistance of BCR/ABL-Expressing Cells to Tyrosine Kinase Inhibitors
by: Janusz Blasiak, et al.
Published: (2013-08-01)

Combination of venetoclax with BCR-ABL tyrosine kinase inhibitor as a therapeutic strategy for Philadelphia chromosome-positive leukemias
by: Jing-Ying Zou, et al.
Published: (2023-12-01)

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
by: Maria Stella Pennisi, et al.
Published: (2019-08-01)

BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia
by: Gustavo P. Amarante-Mendes, et al.
Published: (2022-01-01)

P660: NEXT-GENERATION SEQUENCING (NGS) FOR DETECTING BCR::ABL-INDEPENDENT MUTATIONS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WITH RESISTANCE TO TYROSINE KINASE INHIBITOR TREATMENT
by: Daria Kustova, et al.
Published: (2023-08-01)

Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia
by: Valeria Ciaffaglione, et al.
Published: (2022-05-01)

Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
by: İbrahim C. Haznedaroğlu
Published: (2013-09-01)

Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors
by: Manuela Mancini, et al.
Published: (2022-08-01)

Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors
by: Valentín García-Gutiérrez, et al.
Published: (2020-07-01)

A customized mass array panel for BCR::ABL1 tyrosine kinase domain mutation screening in chronic myeloid leukemia
by: Nittaya Limsuwanachot, et al.
Published: (2023-04-01)

Prognostic significance of a normal karyotype in adult patients with BCR-ABL1-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era
by: Ting Shi, et al.
Published: (2020-11-01)

DISCONTINUATION OF TYROSINE KINASE INHIBITORS IN TUNISIAN CHRONIC MYELOID LEUKEMIA PATIENTS
by: Rim FRIKHA, et al.
Published: (2023-10-01)

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors
by: İbrahim C. Haznedaroğlu, et al.
Published: (2020-02-01)

Tyrosine kinase inhibitors induced immune thrombocytopenia in chronic myeloid leukemia?
by: Avital F. Barak, et al.
Published: (2011-12-01)

Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinase Exerts Synergistic Effect against Chronic Myeloid Leukemia Cells
by: Sylwia Flis, et al.
Published: (2019-10-01)

Committed change of real-time quantitative PCR to droplet digital PCR for monitoring BCR::ABL1 transcripts in tyrosine kinase inhibitor treated CML
by: Adcharee Kongruang, et al.
Published: (2023-12-01)

Bruton’s Tyrosine Kinase Inhibitors: Recent Updates
by: Amneh Fares, et al.
Published: (2024-02-01)

Tyrosine Kinase Inhibitors Target B Lymphocytes
by: Nikki Lyn Esnardo Upfold, et al.
Published: (2023-02-01)

Spheroacanthocytes secondary to novel tyrosine kinase inhibitors
by: Michael Ashby, et al.
Published: (2020-11-01)

Tyrosine kinase inhibitor Tofacitinib. Safety issues
by: G. V. Lukina, et al.
Published: (2015-12-01)

Molecular genetics monitoring of tyrosine kinase inhibitor therapy for chronic myeloid leukemia
by: S. I. Kutsev, et al.
Published: (2022-11-01)

Features of the etythropoesis upon treatment of chronic myeloid leukemia with tyrosine kinase inhibitor
by: I. Sviezhentseva, et al.
Published: (2016-07-01)

Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors - a single center experience
by: Beatriz Felicio Ribeiro, et al.
Published: (2015-08-01)

High resolution melt curve analysis as a tool for screening tyrosine kinase domain mutations in patients with chronic myeloid leukemia on tyrosine kinase inhibitors
by: Ang, C.H., et al.
Published: (2010)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
by: Yu Yao, et al.
Published: (2023-01-01)

The two facets of receptor tyrosine kinase in cardiovascular calcification—can tyrosine kinase inhibitors benefit cardiovascular system?
by: Ainun Nizar Masbuchin, et al.
Published: (2022-09-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
by: Xu H, et al.
Published: (2019-07-01)

Concurrent use of tumor necrosis factor inhibitor and tyrosine kinase inhibitor in ankylosing spondylitis and myeloid neoplasm
by: Akash Gupta, et al.
Published: (2022-10-01)

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
by: Huang JT, et al.
Published: (2022-11-01)

The Direct and Indirect Effects of Tyrosine Kinase Inhibitors on the Cardiovascular System in Chronic Myeloid Leukemia
by: Alessandro Costa, et al.
Published: (2023-07-01)

Pharmacokinetics of Four Tyrosine Kinase Inhibitors in Adult and Paediatric Chronic Myeloid Leukaemia Patients
by: Sarah Allegra, et al.
Published: (2023-09-01)

Chronic Myeloid Leukemia in Children and Adolescents: The Achilles Heel of Oncogenesis and Tyrosine Kinase Inhibitors
by: Maria Moschovi, et al.
Published: (2021-07-01)

Outcomes of the Pregnancies with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era and Literature Review
by: Dan Ran Castillo, et al.
Published: (2022-03-01)